The Latest Medical News

A Summary of The Latest Medical News: Earlier this week, an international consortium of clinicians, researchers and patient‐advocates announced that “polycystic ovary syndrome” (PCOS) will be rebranded as “polyendocrine metabolic ovarian syndrome” (PMOS). This change is designed to: 1. Emphasize the underlying endocrine-metabolic drivers—particularly insulin resistance and inflammation—rather than focusing narrowly on ovarian cysts or menstrual irregularity. 2. Encourage earlier, more holistic screening for associated risks (obesity, type 2 diabetes, cardiovascular disease, fatty liver, mood disorders). 3. Reduce stigma by moving away from the moniker “polycystic,” which for many women can misleadingly imply that ovarian cysts are the core problem. Key points • Scope: The expert panel included endocrinologists, gynecologists, primary-care physicians, dietitians and patient-partners from more than 20 countries. • Rationale: Decades of research have shown that up to 70% of people with PCOS have significant metabolic dysfunction—even if polycystic ovaries aren’t obvious on ultrasound. • Next steps: Over the coming 6–12 months, major professional bodies (e.g. Endocrine Society, American College of Obstetricians & Gynecologists, international diabetes federations) will begin updating their guidelines, patient-education materials and billing codes. • Patient impact: In theory, the new name should prompt clinicians to: – Screen all patients with PMOS for insulin resistance, glucose intolerance and cardiovascular risk factors from the time of diagnosis. – Offer earlier lifestyle, nutritional and, when appropriate, pharmacologic interventions (e.g. metformin, GLP-1 agonists). – Coordinate care across specialties (endocrinology, cardiology, dermatology, mental health). What’s unchanged • The core diagnostic criteria—irregular ovulation, hyperandrogenic signs and metabolic markers—remain the same, as do first-line treatments such as weight management and insulin-sensitizing agents. • Until professional societies roll out formal “PMOS” guidelines, many practitioners will still use the term PCOS in both charts and patient conversations. Bottom line The shift to “polyendocrine metabolic ovarian syndrome” is meant to reflect current science and—and ultimately—improve long-term outcomes. Over the next year, you can expect to see more educational programs, updated clinical protocols and a gradual move in both medical literature and patient materials toward PMOS. Help with your insurance? https://tally.so/r/n012P9

The Latest from Medicare

Welcome to our article summary! In this concise overview, we will distill the key points and insights from the original piece, providing you with a clear understanding of the main themes and arguments. Whether you're looking for a quick recap or a deeper insight into the topic, this summary will highlight the essential information you need to know. Let's dive in!Hello! It looks like you’re viewing information on how to contact Medicare by phone or live chat. If you’d like to speak with a real person, Medicare’s National Customer Service Center is available 24 hours a day, 7 days a week (except some federal holidays). • Phone: 1-800-MEDICARE (1-800-633-4227) • TTY users: 1-877-486-2048 • Live chat: Visit www.medicare.gov and click “Live Chat” How can I assist you with your Medicare questions today? Help with your insurance? https://tally.so/r/n012P9

Retirement Concerns on Aging

Are you getting to that point in life where age has become a concern? Read on!!!On March 27, the Human Rights Campaign Foundation’s Health & Aging team and SAGE were recognized by the American Society on Aging (ASA) for our groundbreaking work advancing the health, well-being and social inclusion of LGBTQ older adults—most notably through our collaborative “Caring & Aging with Pride” research and the accompanying cultural-competency training series for aging-services providers.

The Latest Medical News

A Summary of The Latest Medical News: Here’s what we know about ArteraAI and its new FDA clearance: 1. What is ArteraAI? • A “multimodal” AI-powered risk assay for early-stage, hormone receptor–positive, HER2-negative breast cancer • Combines data from: – Digital pathology (scanned H&E slides) – Gene-expression profiling of the tumor – Basic clinical parameters (e.g. tumor size, grade, patient age) • Developed by Paige and collaborators to give a single risk score for recurrence 2. How it works • Deep-learning models analyze tissue architecture in whole-slide images • A separate machine-learning model interprets expression levels of a panel of cancer-related genes • Outputs a risk category (low, intermediate, or high) that correlates with 10-year recurrence probability • Intended to guide discussions about whether adjuvant chemotherapy is likely to provide benefit 3. Key validation findings • Retrospective study of several hundred patients whose risk categories were already known • Strong concordance with existing genomic tests (e.g. Oncotype DX) but with the addition of histology features • Low-risk patients had very low 10-year recurrence rates without chemotherapy, suggesting some can safely skip chemo • FDA granted clearance based on analytical and clinical validation under its de novo pathway 4. Potential benefits • Reduces overtreatment—avoiding chemo’s side effects (neuropathy, fatigue, cognitive “chemo-brain”) in patients unlikely to benefit • Speeds turnaround by leveraging a single digital slide plus a small gene panel • Offers a more holistic tumor profile than tests relying solely on gene expression 5. Limitations and next steps • Approved only for the specific subtype (early-stage HR-positive, HER2-negative, node-negative) • Further real-world studies needed to confirm benefits across diverse patient populations and clinical settings • Should not replace physician judgment—best used as one component of a multidisciplinary treatment discussion 6. What this means for patients • If your oncologist recommends a recurrence-risk assay, ArteraAI may be an option, especially if you’re deemed low or intermediate risk • Always review test results in the context of your overall health, preferences, and treatment goals • Discuss with your care team whether an AI-driven assay fits into your personalized treatment plan Disclaimer: This summary is for informational purposes only and does not constitute medical advice. Always consult your oncology team before making treatment decisions. Help with your insurance? https://tally.so/r/n012P9

The Latest Medical News

A Summary of The Latest Medical News: Here’s a quick breakdown of what this new study tells us—and why it matters: 1. What is intermuscular fat? • It’s fat that collects between and within muscle fibers, not just under the skin or around organs. • Often invisible to the naked eye, it can quietly impair muscle function and metabolism. 2. How did researchers measure it? • They ran hundreds of whole-body MRI scans through a deep-learning (AI) pipeline. • The AI models segmented out muscle tissue and then quantified the tiny deposits of fat interwoven in and between muscles. 3. What did they find? • After adjusting for age, sex, overall body fat, and other risk factors, people with higher intermuscular fat had: – Worse insulin sensitivity – Higher blood pressure – More adverse lipid profiles (e.g., higher triglycerides) – A greater overall cardiometabolic risk score • These links held true even in people whose BMI or waist circumference were “normal.” 4. Why does it matter? • It helps explain why two people with the same BMI can have very different metabolic health. • Intermuscular fat releases inflammatory signals and fatty acids that interfere with muscle glucose uptake. • Identifying it could spot high-risk individuals long before overt diabetes or heart disease develops. 5. Clinical and lifestyle implications • Screening: Future MRI-AI tools might flag hidden high‐risk fat patterns without expensive biopsies. • Prevention: Resistance training and high-intensity interval exercise seem especially good at blasting intermuscular fat. • Diet: Protein-sparing diets (adequate protein, moderate carbs, healthy fats) help maintain muscle mass and reduce fat infiltration. 6. Next steps in research • Longitudinal studies to see whether reducing intermuscular fat actually lowers heart-disease or diabetes incidence. • Trials comparing different exercise and nutrition interventions head-to-head. • Integrating this measure into routine risk-stratification models alongside traditional markers. Bottom line: Beyond BMI and waist size, “hidden” fat inside our muscles may be an independent driver of metabolic and cardiovascular disease—and AI-powered imaging is finally giving us a window into it. Help with your insurance? https://tally.so/r/n012P9

The Latest Medical News

A Summary of The Latest Medical News: The procedure in question is most often arthroscopic “clean‐up” surgery—that is, debridement (removal of loose cartilage fragments or smoothing of rough surfaces) with or without partial meniscectomy—performed in hopes of reducing pain and improving function in osteoarthritic knees. Here’s what the recent Finnish study and the broader evidence tell us: 1. What the Finnish study did and found • Population: Patients aged 35–65 with radiographic knee osteoarthritis and mechanical symptoms (catching, locking), randomized to either arthroscopic debridement / meniscectomy or non-operative care. • Follow-up: MRI and X-ray assessments at 12 and 24 months. • Result: Those who underwent arthroscopy showed slightly greater joint‐space narrowing and cartilage loss on MRI, suggesting accelerated structural progression of OA, and no clear extra symptom relief compared to the non-operative group. 2. Why arthroscopy may fail in OA • Cartilage in osteoarthritis is already thinning and roughened—scraping it more can exacerbate damage. • Removing part of the meniscus can overload the joint surface biomechanically. • Arthroscopic lavage (flushing) doesn’t address the underlying inflammatory and metabolic processes of OA. 3. What current guidelines say • Major orthopedic and rheumatology societies (AAOS, EULAR, OARSI) recommend against routine arthroscopic lavage or debridement for typical OA pain. • Indications for arthroscopy are now usually limited to acute mechanical problems (e.g. a locked bucket‐handle meniscal tear in an otherwise non-arthritic knee). 4. Non-surgical alternatives • Exercise therapy (quadriceps and hip-strengthening) • Weight management if BMI ≥ 25 • Bracing or laterally/unloader-type knee braces • Intra-articular injections (corticosteroids, hyaluronic acid) after discussing risks/benefits • Oral pain relievers (acetaminophen, NSAIDs) and careful monitoring 5. If you’re considering surgery • Seek a second opinion or ask specifically whether your surgeon still recommends arthroscopy for OA. • Discuss realistic outcomes: most studies show only small short-term benefits in pain and function, not long-term structural improvement. • Explore a structured physical therapy program first—many patients get as much relief from PT as from arthroscopy without the surgical risks. Disclaimer: This information is descriptive only. Always talk to your orthopedic specialist or rheumatologist about what’s best for your individual situation. Help with your insurance? https://tally.so/r/n012P9

Retirement Concerns on Aging

Are you getting to that point in life where age has become a concern? Read on!!!Alt text (for screen readers): A middle-aged woman sits at a kitchen table strewn with medical bills, paperwork and a calculator. She holds her forehead in one hand and a phone in the other, her expression weary and worried. Caption: At the AARP Foundation’s recent gathering, experts underscored two urgent issues facing millions of American families—mounting health-care debt that can derail household budgets, and the hidden costs borne by paid family caregivers who juggle work, care and often insufficient pay.